HER3 in cancer: from the bench to the bedside

Overview of attention for article published in Journal of Experimental & Clinical Cancer Research, October 2022

Altmetric Badge

About this Attention Score

In the top 25% of all research outputs scored by Altmetric
High Attention Score compared to outputs of the same age (88th percentile)
High Attention Score compared to outputs of the same age and source (93rd percentile)

Mentioned by

news: 2 news outlets

twitter: 3 X users

Citations

dimensions_citation: 24 Dimensions

Readers on

mendeley: 41 Mendeley

Summary News X Dimensions citations

So far, Altmetric has seen 3 news stories from 2 outlets.

Elevation Oncology: Mid-2024 EO-3021 Data Could Get Ball Rolling

Seeking Alpha, 03 May 2024

Follow Summary Results from the phase 1 study, using EO-3021 for the treatment of CLDN 18.2 expressing solid tumors, expected…

BioNTech's Strategic Shift: Diversifying Into Cancer Therapeutics

Seeking Alpha, 28 Dec 2023

Follow Summary BioNTech is diversifying its portfolio beyond its COVID-19 vaccine, focusing on antibody-drug conjugates (ADCs…

Merck Pays $4B Upfront for Daiichi Sankyo’s DXd-Based ADCs

Biospace, 20 Oct 2023

Pictured: Merck building in California/iStock, Sundry Photography Merck and Daiichi Sankyo on Thursday signed a global…

This page shows the most recent news stories that mention this research output.

Click here to find out how to access more activity.